Tony Mok Buys 1,500 Shares of AstraZeneca PLC (LON:AZN) Stock

AstraZeneca PLC (LON:AZN) insider Tony Mok purchased 1,500 shares of the business’s stock in a transaction on Tuesday, November 19th. The stock was purchased at an average price of £126.80 ($159.64) per share, with a total value of £190,200 ($239,456.12).

AstraZeneca Price Performance

LON:AZN opened at £100.62 ($126.68) on Friday. AstraZeneca PLC has a 52 week low of GBX 9,461 ($119.11) and a 52 week high of £133.88 ($168.55). The firm has a market cap of £155.96 billion, a price-to-earnings ratio of 3,194.29, a P/E/G ratio of 0.86 and a beta of 0.17. The firm’s 50-day simple moving average is £113.96 and its 200 day simple moving average is £120.77. The company has a debt-to-equity ratio of 84.97, a quick ratio of 0.59 and a current ratio of 0.89.

Analysts Set New Price Targets

A number of analysts have commented on AZN shares. Berenberg Bank reiterated a “buy” rating and issued a £150 ($188.85) price target on shares of AstraZeneca in a research note on Monday, September 2nd. JPMorgan Chase & Co. reissued an “overweight” rating and issued a £140 ($176.26) price objective on shares of AstraZeneca in a research report on Thursday, November 7th. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research report on Thursday, November 7th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a £110 ($138.49) price objective on shares of AstraZeneca in a research report on Tuesday, September 3rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of £104.12 ($131.09).

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.